XRTX XORTX Therapeutics Inc. Common Stock · XNAS
2.27 +7.8% as of Sep 11, 14:55 ET
fans
What's happening Live detector signal Generated 19:57 ET
Share structure
Free float
1.7M
2026-08-14
Shares out
1.8M
latest detail
Market cap
$3.8M
at ref price
Short interest
0.8%
2026-08-31
Float rotation
0.98×
latest snapshot
20d dollar vol
$209.5K
baseline
Supply intelligence
Gap quality
squeeze-prone · 92
live supply-pressure model
Supply factor
very tight float
detector reason
Supply factor
heavy float rotation
detector reason
Supply factor
nano-cap supply profile
detector reason

This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.

Filings and news
2026-09-11 14:55 ETSignalXORTX Therapeutics Inc. Common Stock is up 7.8%, at 2.27, on $3.9M traded, 19.8× 20-day volume, 0.98× float rotation. Score 76. Primary driver: 97.7% float rotation. Supply intelligence: squeeze-prone · 92.
2026-08-28 07:00 ETFDA / ClinicalXORTX Announces Termination and Postponement of Investor Relations Program News
2026-06-12 17:00 ETGeneralXORTX Announces Election to Voluntary Delist from the TSX Venture Exchange News
2026-05-13EFFECTPotential financing or dilution-related filing. SEC
2026-04-13 17:00 ETFDA / ClinicalXORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset News
2026-04-06Split1-for-5 reverse split logged
2026-04-01 13:00 ETFDA / ClinicalXORTX Confirms Effective Date of Share Consolidation News
2026-02-17EFFECTPotential financing or dilution-related filing. SEC
2025-10-23424B5Potential financing or dilution-related filing. SEC
2024-12-13424B5Potential financing or dilution-related filing. SEC
2024-11-25EFFECTPotential financing or dilution-related filing. SEC
2024-11-22424B3Potential financing or dilution-related filing. SEC
Latest detector signalscore 76
score 76